Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Deutsches Krebsforschungszentrum

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Benjamin Bader

Philip Lienau

Gerhard Siemeister

Marcus Koppitz

Antje Margret Wengner

Hans Briem

Dirk Kosemund

Detlef Stöckigt

Julien Lefranc

Ulf Bömer

Knut Eis

Stefan Prechtl

Ulrich Lücking

Norbert Schmees

Michael Platten

Lars Röse

Hans Schick

Ludwig Zorn

Volker Schulze

Wilhelm Bone

Lars Wortmann

Ulrich Klar

Rolf Bohlmann

Rolf Jautelat

Joanna Grudzinska-Goebel

Duy Nguyen

Hartmut Schirok

Judith Günther

Simon Holton

Olaf Prien

Tobias Marquardt

Nicolas Werbeck

Stuart Ince

Kirstin Petersen

Antonius Ter Laak

William Johnston Scott

Wolfgang Schwede

Lars Bärfacker

Anne Mengel

Jens Ackerstaff

Ursula Mönning

Ingo Hartung

Clara Christ

Holger Siebeneicher

Franz Von Nussbaum

Ursula Moenning

Bernard Jacques Haendler

Ilona Gutcher

Ulrike Röhn

Dieter Moosmayer

Horst Irlbacher

Uwe Eberspächer

Christina Kober

Rafael Carretero

Tobias Heinrich

Dennis Kirchhoff

Roman Hillig

Rienk Offringa

Christof Wegscheid-Gerlach

Mareike Grees

Hermann Kuenzer

Dieter Zopf

Christoph Huwe

Reinhard Nubbemeyer

Antje Rottmann

Arne Von Bonin

Jens Schröder

Holger Steuber

Ildiko Terebesi

Katrin Nowak-Reppel

Niels Böhnke

Judith Guenther

Martin Fritsch

Michaele Peters

Manfred Husemann

Hermann Künzer

Bertolt Kreft

Arndt Schmitz

Christian Lechner

Andrea Wagenfeld

Silke Köhr

William Scott

Hortensia Faus Gimenez

Na Zhao

Ulrich Zügel

Karina Schuck

Florian Prinz

Thi Thanh Uyen Nguyen

Joszef Bálint

Ulf Boemer

Corinna Link

Ulrike Roehn

Katrin Nowak-reppel

Detlef Stoeckigt

Giambattista Testolin

Florian Pühler

Ulrich Rosentreter

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminoquinolones as DGKalpha inhibitors for immune activation

The present invention covers aminothiazole compounds of general formula (I), in which R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGKζ) regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminothiazoles as DGKzeta inhibitors for immune activation

The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

The present invention covers 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R, R, R, R, R, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

2-phenylpyrimidine-4-carboxamides as AHR inhibitors

Disclosed are compounds of general formula (I): wherein R, R, A, X, Y and Z are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds and the use of the compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.

[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

The present invention relates to isothiazoles of general formula (I) which inhibit the mitotic checkpoint: in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Amino-substituted isothiazoles

Growing community of inventors

Berlin, Germany

Benjamin Bader